knowledge -WSS

knowledge

author：explore 2025-10-01 23:39:18 - browse：85

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Most antidepressants don't work on kids, teens, study finds

WSS

Deliver public health messages at the right time

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Brain technologies pose threats that are all too real, experts warn

How digital tools helped lower hypertension in marginalized patients

How digital tools helped lower hypertension in marginalized patients

Medicare threatens to cut off funding for HCA's Mission hospital

Wikipedia

knowledge

leisure time

How to save PrEP access — and even expand it

Can gargling with Listerine treat gonorrhea of the mouth?

How one medical school became remarkably diverse

KalVista pill reduced swelling 'attacks' caused by genetic disease

United colonoscopy coverage change 'may cost lives,' doctors say

The effects of a landmark ruling on DNA ownership are becoming clearer

At least 13 dead in Texas as scorching temps continue

Readout LOUD podcast: How biotech is using artificial intelligence

How to save PrEP access — and even expand it

AltruBio raises $225 million to develop ulcerative colitis drug

hotspot

For Medicare Advantage, Democrats want stronger protections around AI

What should King Charles tell the public about his cancer?

Industry veterans launch new biotech VC with $310M

As billionaires fund anti

Why did Pfizer dish out millions for a Super Bowl ad?

Class action alleges UnitedHealth concealed DOJ probe

Wikipedia

leisure time

hotspot

focus